Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors.
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D045744:Cell Line, Tumor; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors / Q000378:metabolism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000276:immunology; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D007700:Kinetics; D007983:Lewis Blood Group Antigens / Q000276:immunology*; D020935:MAP Kinase Signaling System / Q000187:drug effects; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D010766:Phosphorylation; D011233:Precipitin Tests; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000276:immunology; D014415:Tunicamycin / Q000494:pharmacology; D014846:Vulvar Neoplasms / Q000276:immunology / Q000378:metabolism / Q000628:therapy
D000911:Antibodies, Monoclonal; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D007457:Iodine Radioisotopes; D007983:Lewis Blood Group Antigens; D020928:Mitogen-Activated Protein Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; D014415:Tunicamycin; C094162:Lewis Y antigen